BNP in SOB
The impact of measuring brain type natriuretic peptide in patients with shortness of breath in the emergency department on management and subsequent patient mortality and morbidity.
Bayside Health
600 participants
Aug 22, 2005
Interventional
Conditions
Summary
To evaluate whether testing levels of BNP in patients presenting with shortness of breath has an impact on the management of these patients in the emergency department
Eligibility
Inclusion Criteria1
- Presenting complaint of SOB, of triage categories 1-3.
Exclusion Criteria1
- Trauma patients, patients with renal failure or patients in cardiogenic shock.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
To evaluate the role of B-type natriuretic peptide (BNP) in the management of patients presenting to the emergency department with the presenting symptom of shortness of breath (SOB). Patients randomised to the study group will have BNP levels tested. In the test group with a positive BNP result doctors will be encouraged to use a standardised approach to the optimum treatment of CCF. Blood is taken for BNP levels upon patient arrival and results will be available within one hour. The study duration is 18 months.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000350628